Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
22.08. | RedHill launches Talicia in UAE to treat H. pylori infection | ||
21.08. | GSK's B7-H3-targeted ADC receives FDA breakthrough therapy status | ||
20.08. | FDA grants Fast Track Designation to Arthrosi Therapeutics's AR882 for gout treatment | ||
19.08. | EMA validates Type II Variation application for ENHERTU for breast cancer treatment | ||
16.08. | Aarvik announces ADC option exercise by collaboration partner ArriVent | ||
14.08. | FDA grants priority review for Bavarian Nordic's chikungunya vaccine BLA | ||
13.08. | Persist AI and Nivagen to develop AI-driven LAI manufacturing process | ||
12.08. | Sandoz's Enzeevu secures FDA approval for nAMD treatment | ||
09.08. | Bavarian Nordic secures $156.8m US vaccine deal | ||
08.08. | US FDA approves Purdue Pharma's Zurnai auto-injector | ||
07.08. | FDA accepts Exelixis' cabozantinib sNDA for neuroendocrine tumours | ||
06.08. | Santen and Cloudbreak enter licence agreement for pterygium treatment | ||
05.08. | Genmab assumes full ownership of acasunlimab | ||
02.08. | Health Canada grants approval for Celltrion's Steqeyma for multiple conditions | ||
01.08. | Jade Biosciences secures $80m to develop autoimmune therapies | ||
31.07. | Pinetree secures $17m to advance TPD development programmes | ||
30.07. | FDA approves Alpha Cognition's ZUNVEYL for Alzheimer's treatment | ||
29.07. | LEO Pharma obtains positive EMA CHMP opinion for eczema treatment | ||
26.07. | Confo Therapeutics secures €60m funds to progress GPCR-modulating therapies | ||
25.07. | Oisín secures funds to advance treatments for age-related ailments | ||
24.07. | FDA grants RMAT designation to AffyImmune's AIC100 for thyroid cancer | ||
23.07. | Vividion Therapeutics to expand capabilities with new R&D centre in US | ||
22.07. | Apollo Therapeutics and University of Oxford sign drug discovery partnership | ||
19.07. | Diamyd Medical secures FDA fast track status for type 1 diabetes treatment | ||
18.07. | Lynch Regenerative Medicine secures funds to develop skin regeneration solutions |